Divestment

Vivendy Therapeutics

Vivendy Therapeutics developed enzyme replacement therapy for the rare lysosomal storage disorder MPS VI (Maroteaux-Lamy syndrome).

Responsible partner
News

Key Facts

Sector: Life Sciences
Country: Switzerland
Fund: LSP 3
Entry: 2007
Exit: 2014

Responsible Partner

Joachim Rothe

Joachim Rothe

Partner

News

October 22, 2025
EQT Life Sciences Co-Leads USD 183 Million Series C Financing in Electra Therapeutics
October 22, 2025
EQT Life Sciences’ ImCheck Therapeutics to be acquired by Ipsen in a transaction valued at up to EUR 1 billion
September 30, 2025
EQT Life Sciences portfolio company Merus to be acquired by Genmab in an all-cash USD 8.0 billion transaction
September 16, 2025
EQT Life Sciences portfolio company VarmX partners with CSL in a strategic collaboration and option agreement worth up to USD 2.2 billion

Do You Want to Know More?

We are eager to explore how we can achieve great things together.

Vivendy Therapeutics | EQT Portfolio